European Patent Granted for Biocept’s Target Selector Oncogene Mutation Enrichment and Detection Platform

This expands their intellectual property to 27 issued patents, globally, for highly sensitive methods of detecting cancer bio-markers in circulating tumour DNA and on circulating tumour cells.

Biocept, Inc. a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it has been granted European Patent No. 2,705,162, entitled “METHODS FOR DETECTING NUCLEIC ACID SEQUENCE VARIANTS.”

The patent provides intellectual property protection in seven European countries and is core to Biocept’s Target Selector™ assays for ctDNA analysis using real-time PCR, Sangersequencing and next-generation sequencing (NGS).

Image result for biocept
Biocept, Inc. is a leading commercial provider of liquid biopsy tests.

Lyle ArnoldBiocept’s Chief Scientific Officer said “The issuance of this patent further expands a series of worldwide patents protecting our proprietary, highly sensitive ctDNA platform technology into several key European countries, which we believe could be important markets for our liquid biopsy tests.

“Our patents related to ultra-sensitive mutation detection, ctDNA analysis and CTC capture, combined with those for our blood transport tubes provide significant international coverage, protecting all three of our core liquid biopsy technology platforms.”

The recently granted European patent encompasses Biocept’s proprietary “switch-blocker” technology, which enriches patient specimens for oncogene mutations of interest, resulting in ultra-high sensitivity and specificity for the detection of cancer-associated alterations.

The switch-blocker technology is designed to improve detection rates for rare cancer associated biomarkers in patients diagnosed with cancer, allowing physicians to make informed decisions for therapy selection and to monitor treatment response, progression or recurrence over time.

Image result for cancer
The switch-blocker technology is designed to improve detection rates for rare cancer

Biocept’s President and CEO, Michael Nall stated “Obtaining this patent provides additional intellectual property protection for the unique and novel features of our Target Selector™ liquid biopsy platform used for ctDNA analysis.

“We now have 27 issued patents globally that cover our core technologies and support our initiative to expand our business into key markets around the world.”


You Might Also Like